{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:56:38Z","timestamp":1792144598095,"version":"4.4.0"},"reference-count":24,"publisher":"Scientific Scholar","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA) has shown to be a promising agent for prostate cancer imaging under PET-CT. With the automation in radiolabeling with 68Ga, using iTG 68Ge\/68Ga generator, it has helped introduce various new diagnostic agents and achieve good manufacturing practices (GMP) simultaneously. However, before any radiopharmaceutical is put into clinical usage, it should always be checked for its radiochemical purity and other quality parameters before injecting in the patient. Chromatography techniques such as Gas Chromatography (GC), High-Performance Liquid Chromatography (HPLC), and Thin-Layer Chromatography (TLC) are the most frequently utilized separation technique for purity analysis. A rapid quality control HPLC based methodology was required for radiopharmaceuticals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim &amp; Objective:<\/jats:title>\n                    <jats:p>In our current setting, we conducted quality control analysis and standardized and validated HPLC method for the routine quality check of 68Ga-PSMA-11.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The QC of 68Ga PSMA-11 was performed under ITLC and HPLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Linearity, accuracy, precision and specificity were assessed and quantified in accordance with International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (Q2 (R1) ICH) guidelines, which can be implemented in resource-limited settings to check the quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The current HPLC based methodology is rapid, with a retention time of 2.24 min, rendering it a favorable analytical standard operating procedure for QC analysis of 68Ga-PSMA-11.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijnm.ijnm_42_24","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:33Z","timestamp":1731888033000},"page":"265-271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Time-efficient HPLC Validation Methodology for the Qualitative Analysis of 68Ga PSMA-11 in Routine Clinical Usage under Isocratic Method"],"prefix":"10.25259","volume":"39","author":[{"given":"Sachin","family":"Tayal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murari","family":"Gurjar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikandan Marappagounder","family":"Venkatachalam","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging, Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"R1-20241118","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"R2-20241118","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R3-20241118","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.7150\/thno.13348","article-title":"PSMA ligands for radionuclide imaging and therapy of prostate cancer: Clinical status","volume":"5","author":"L\u00fctje","year":"2015","journal-title":"Theranostics"},{"key":"R4-20241118","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2967\/jnumed.115.157339","article-title":"PSMA PET in prostate cancer","volume":"56","author":"Jadvar","year":"2015","journal-title":"J Nucl Med"},{"key":"R5-20241118","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41181-021-00123-2","article-title":"Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals","volume":"6","author":"Gillings","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"key":"R6-20241118","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20241118","first-page":"75","article-title":"Gallium-68 DOTATATE production with automated PET radiopharmaceutical synthesis system: A three year experience","volume":"2","author":"Aslani","year":"2014","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"R8-20241118","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nucmedbio.2016.05.006","article-title":"Preparation of [(68) Ga] PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based (68) Ge\/(68) Ga generator","volume":"43","author":"Nanabala","year":"2016","journal-title":"Nucl Med Biol"},{"key":"R9-20241118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/ijnm.ijnm_7_21","article-title":"Installation and optimization of (68) Ga synthesis module for clinical use: An institutional experience","volume":"36","author":"Tayal","year":"2021","journal-title":"Indian J Nucl Med"},{"key":"R10-20241118","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00259-010-1407-3","article-title":"Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals","volume":"37","author":"Elsinga","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20241118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41181-019-0086-z","article-title":"EANM guideline on the validation of analytical methods for radiopharmaceuticals","volume":"5","author":"Gillings","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"key":"R12-20241118","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1007\/s00259-019-04322-7","article-title":"[(68) Ga] Pentixafor PET\/MR imaging of chemokine receptor 4 expression in the human carotid artery","volume":"46","author":"Li","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20241118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41181-018-0052-1","article-title":"Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals","volume":"4","author":"de Blois","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"R18-20241118","first-page":"569","article-title":"A rapid HPLC method for the determination of losartan in human plasma using a monolithic column","volume":"55","author":"Zarghi","year":"2005","journal-title":"Arzneimittelforschung"},{"key":"R20-20241118","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/pharmaceutics13050715","article-title":"Development of [(225) Ac] Ac-PSMA-I and T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC","volume":"13","author":"Hooijman","year":"2021","journal-title":"Pharmaceutics"},{"key":"R21-20241118","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nucmedbio.2017.07.006","article-title":"Continuation of comprehensive quality control of the itG (68) Ge\/(68) Ga generator and production of (68) Ga-DOTATOC and (68) Ga-PSMA-HBED-CC for clinical research studies","volume":"53","author":"Amor-Coarasa","year":"2017","journal-title":"Nucl Med Biol"},{"key":"R24-20241118","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/ph14080713","article-title":"[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer","volume":"14","author":"Hennrich,","year":"2021","journal-title":"Pharmaceuticals (Basel),"},{"key":"R25-20241118","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4103\/ijnm.IJNM_66_20","article-title":"Validation of quality control parameters of cassette-based gallium-68-DOTA-Tyr3-octreotate synthesis","volume":"35","author":"Sammartano","year":"2020","journal-title":"Indian J Nucl Med"},{"key":"R26-20241118","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1021\/acsomega.7b00677","article-title":"Development and validation of a high-pressure liquid chromatography method for the determination of chemical purity and radiochemical purity of a [(68) Ga]-labeled Glu-Urea-Lys (Ahx)-HBED-CC (positron emission tomography) tracer","volume":"2","author":"Migliari","year":"2017","journal-title":"ACS Omega"},{"key":"R27-20241118","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.118.212720","article-title":"Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I and F for nuclear and fluorescence imaging of prostate cancer","volume":"60","author":"Schottelius","year":"2019","journal-title":"J Nucl Med"},{"key":"R28-20241118","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/ph15030343","article-title":"Optimization of precursor preparation in PSMA-11 radiolabeling to obtain a highly reproducible radiochemical yield","volume":"15","author":"Iudicello","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R29-20241118","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jlcr.3227","article-title":"Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: A European perspective","volume":"57","author":"Aerts","year":"2014","journal-title":"J Labelled Comp Radiopharm"},{"key":"R30-20241118","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/wjnm.WJNM_82_18","article-title":"Quality control and GMP synthesis of (68) Ga-prostate-specific membrane antigen-11 for detection of low-and high-grade prostate cancer","volume":"19","author":"Assadi","year":"2020","journal-title":"World J Nucl Med"},{"key":"R31-20241118","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/ph14050385","article-title":"Standardization of the [(68) Ga] Ga-PSMA-11 radiolabeling protocol in an automatic synthesis module: Assessments for PET imaging of prostate cancer","volume":"14","author":"Fuscaldi","year":"2021","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Indian Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijnm.ijnm_42_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:38:15Z","timestamp":1779694695000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijnm.co.in\/time-efficient-hplc-validation-methodology-for-the-qualitative-analysis-of-68ga-psma-11-in-routine-clinical-usage-under-isocratic-method\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijnm.ijnm_42_24","relation":{},"ISSN":["0972-3919","0974-0244"],"issn-type":[{"value":"0972-3919","type":"print"},{"value":"0974-0244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-04-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}